128 related articles for article (PubMed ID: 38636303)
21. DDB2 represses ovarian cancer cell dedifferentiation by suppressing ALDH1A1.
Cui T; Srivastava AK; Han C; Wu D; Wani N; Liu L; Gao Z; Qu M; Zou N; Zhang X; Yi P; Yu J; Bell EH; Yang SM; Maloney DJ; Zheng Y; Wani AA; Wang QE
Cell Death Dis; 2018 May; 9(5):561. PubMed ID: 29752431
[TBL] [Abstract][Full Text] [Related]
22. TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.
Escalona RM; Bilandzic M; Western P; Kadife E; Kannourakis G; Findlay JK; Ahmed N
BMC Cancer; 2020 Oct; 20(1):960. PubMed ID: 33023532
[TBL] [Abstract][Full Text] [Related]
23. High NRF2 level mediates cancer stem cell-like properties of aldehyde dehydrogenase (ALDH)-high ovarian cancer cells: inhibitory role of all-trans retinoic acid in ALDH/NRF2 signaling.
Kim D; Choi BH; Ryoo IG; Kwak MK
Cell Death Dis; 2018 Aug; 9(9):896. PubMed ID: 30166520
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of CD133-Sustained Chemoresistant Cancer Stem-Like Cells in Human Ovarian Carcinoma.
Liu CL; Chen YJ; Fan MH; Liao YJ; Mao TL
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899775
[TBL] [Abstract][Full Text] [Related]
25. Poziotinib suppresses ovarian cancer stem cell growth via inhibition of HER4-mediated STAT5 pathway.
Lee H; Kim JW; Choi DK; Yu JH; Kim JH; Lee DS; Min SH
Biochem Biophys Res Commun; 2020 May; 526(1):158-164. PubMed ID: 32201081
[TBL] [Abstract][Full Text] [Related]
26. MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.
Zanotti L; Romani C; Tassone L; Todeschini P; Tassi RA; Bandiera E; Damia G; Ricci F; Ardighieri L; Calza S; Marchini S; Beltrame L; Tognon G; D'Incalci M; Pecorelli S; Sartori E; Odicino F; Ravaggi A; Bignotti E
BMC Cancer; 2017 May; 17(1):366. PubMed ID: 28545541
[TBL] [Abstract][Full Text] [Related]
27. RAD18 promotes the migration and invasion of esophageal squamous cell cancer via the JNK-MMPs pathway.
Zou S; Yang J; Guo J; Su Y; He C; Wu J; Yu L; Ding WQ; Zhou J
Cancer Lett; 2018 Mar; 417():65-74. PubMed ID: 29306013
[TBL] [Abstract][Full Text] [Related]
28. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.
Abubaker K; Latifi A; Luwor R; Nazaretian S; Zhu H; Quinn MA; Thompson EW; Findlay JK; Ahmed N
Mol Cancer; 2013 Mar; 12():24. PubMed ID: 23537295
[TBL] [Abstract][Full Text] [Related]
29. Long non-coding RNA LINC00858 aggravates the oncogenic phenotypes of ovarian cancer cells through miR-134-5p/RAD18 signaling.
Xue H; Wu Z; Rao D; Zhuo B; Chen Q
Arch Gynecol Obstet; 2020 Nov; 302(5):1243-1254. PubMed ID: 32875345
[TBL] [Abstract][Full Text] [Related]
30. Tumor suppressor miR-145 reverses drug resistance by directly targeting DNA damage-related gene RAD18 in colorectal cancer.
Liu RL; Dong Y; Deng YZ; Wang WJ; Li WD
Tumour Biol; 2015 Jul; 36(7):5011-9. PubMed ID: 25913620
[TBL] [Abstract][Full Text] [Related]
31. Enrichment for chemoresistant ovarian cancer stem cells from human cell lines.
Cole JM; Joseph S; Sudhahar CG; Cowden Dahl KD
J Vis Exp; 2014 Sep; (91):51891. PubMed ID: 25285606
[TBL] [Abstract][Full Text] [Related]
32. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.
Steg AD; Bevis KS; Katre AA; Ziebarth A; Dobbin ZC; Alvarez RD; Zhang K; Conner M; Landen CN
Clin Cancer Res; 2012 Feb; 18(3):869-81. PubMed ID: 22142828
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
[TBL] [Abstract][Full Text] [Related]
34. An active IGF-1R-AKT signaling imparts functional heterogeneity in ovarian CSC population.
Singh RK; Dhadve A; Sakpal A; De A; Ray P
Sci Rep; 2016 Nov; 6():36612. PubMed ID: 27819360
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin induces stemness in ovarian cancer.
Wiechert A; Saygin C; Thiagarajan PS; Rao VS; Hale JS; Gupta N; Hitomi M; Nagaraj AB; DiFeo A; Lathia JD; Reizes O
Oncotarget; 2016 May; 7(21):30511-22. PubMed ID: 27105520
[TBL] [Abstract][Full Text] [Related]
36. RNF144A suppresses ovarian cancer stem cell properties and tumor progression through regulation of LIN28B degradation via the ubiquitin-proteasome pathway.
Li Y; Wang J; Wang F; Chen W; Gao C; Wang J
Cell Biol Toxicol; 2022 Oct; 38(5):809-824. PubMed ID: 33978933
[TBL] [Abstract][Full Text] [Related]
37. CD44
Sihombing UHM; Andrijono A; Purwoto G; Gandamihardja S; Harahap AR; Rustamadji P; Kekalih A; Widyawati R; Fuady DR
J Egypt Natl Canc Inst; 2022 Oct; 34(1):44. PubMed ID: 36274112
[TBL] [Abstract][Full Text] [Related]
38. RAD18 mediates resistance to ionizing radiation in human glioma cells.
Xie C; Wang H; Cheng H; Li J; Wang Z; Yue W
Biochem Biophys Res Commun; 2014 Feb; 445(1):263-8. PubMed ID: 24518219
[TBL] [Abstract][Full Text] [Related]
39. Calcium Channels as Novel Therapeutic Targets for Ovarian Cancer Stem Cells.
Lee H; Kim JW; Kim DK; Choi DK; Lee S; Yu JH; Kwon OB; Lee J; Lee DS; Kim JH; Min SH
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230901
[TBL] [Abstract][Full Text] [Related]
40. Combined Poziotinib with Manidipine Treatment Suppresses Ovarian Cancer Stem-Cell Proliferation and Stemness.
Lee H; Kim JW; Lee DS; Min SH
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
